ATYR
aTYR PHARMA INC
NASDAQ · Healthcare · Biotechnology · US
$0.37
−2.18%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.38
From 52W high−65.25%
Volume1.13M
Market cap$36.13M
P/E (TTM)—
P/S (TTM)190.1x
Div yield—
Key dataSep 18, 2026
Open
$0.38
From 52W high
−65.25%
Volume
1.13M
Market cap
$36.13M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
26.3
MomentumView details →
1D Return
−2.18%
YTD Return
−53.88%
SummaryUpdated Jun 1, 2026
aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California. The company specializes in discovering and developing novel medicines based on immunological pathways, with a particular focus on treating rare inflammatory and fibrotic diseases. aTyr has evolved from its early research into aminoacyl-tRNA synthetases to become a focused developer of potential treatments for serious lung diseases, with its lead candidate efzofitimod currently in late-stage clinical trials for pulmonary sarcoidosis.
Similar companies
Latest newsMore news →
DelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.12d agoaTyr Pharma provided an update on the expected timing of an FDA response to its protocol submitted in June 2026 for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.19d agoaTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to support its efzofitimod program in ILD.44d ago